SwedenBIO is the industry organization for the life science industry in Sweden. It creates effective contact points, builds knowledge, and provides a strong voice for the industry.

SwedenBIO

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Friedrich Bayer

Johann Friedrich Weskott

Bayer Aktiengesellschaft

CELLINK is a leading 3D bioprinting company committed to providing advanced 3D bioprinting products, services, and technologies to understand and master biology. The company develops technologies that democratize 3D bioprinting, providing leading researchers with the tools to create the future of health.

Erik Gatenholm

Hector Martinez

CELLINK

SwedenBIO is an industry organization for the life science sector. It creates effective networks, builds knowledge, and provides a strong voice for the industry.

SwedenBIO | 15,319 followers on LinkedIn. The national organisation of the life science industry in Sweden  | SwedenBIO helps innovative companies succeed! 
SwedenBIO improves the business climate for our 300+ member companies and the life science industry. In addition to advocacy and promotion of industry interests, through our member services we enable professional development, knowledge and experience exchange.

Verksamhetsledare på STUNS Life science - för hållbar tillväxt inom life science och hälsa

Björn Arvidsson

CEO Strike Pharma AB

Marten Winge

Director General & CEO SwedenBio

Jessica Martinsson

CEO Tyresta Forest Foundation. Superintendent Tyresta National park.

Jonas Ekstrand

Making Sweden a leading life science nation 🇸🇪 🚀 That was the topic of last weeks conference organized by AstraZeneca and GoCo Health Innovation City . The key note speaker Jeanette Edblad presented the updated life science strategy that the government recently launched. She stressed the importance of the industry for the Swedish economy and the engagement from the ministers involved in the long term competitiveness of #Swedish #lifescience . Our CEO Jessica Martinsson participated in a panel discussion around innovation culture and its key elements. She highlighted the value of Swedish production and how this is a vital part of the innovation that Sweden delivers. Thanks to EY and Thomas Straumitz and Linda Andersson for making the bold statement: "What does great look like? – Like Sweden".

18 to 24 November is 𝗪𝗼𝗿𝗹𝗱 𝗔𝗠𝗥 𝗔𝘄𝗮𝗿𝗲𝗻𝗲𝘀𝘀 𝗪𝗲𝗲𝗸 - Educate. Advocate. Act now. Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result of drug resistance, modern healtcare may not be able to perform surgery, treat cancer patients and patients with chronic disease as effectively as we are used to. 18-24 November each year, the World Antimicrobial Awareness Week (WAAW) aims to increase awareness of global antimicrobial resistance (AMR) and to encourage best practices among the general public, health workers, farmers, animal health professionals and policy makers to avoid the further emergence and spread of drug-resistant infections. SwedenBIO is actively working through our working group for Pandemic Preparedness and the Swedish Industry Alliance against AMR to increase Swedish capabilities in handling antimicrobial resistance. Through these constellations we develop policies and frameworks that highlight the solutions the industry can contribute with in order to tackle the AMR challenge. International Council of Biotechnology Associations (ICBA) #WAAW #AntimicrobialResistance #AMR #HandleWithCare #dentystapandemin

The life science innovation gap between the EU and its global competitors continues to widen while the number of EU regulations affecting the industry is rising. Are we heading in the right direction? Read the opinion column by SwedenBIOs CEO Jessica Martinsson in Nordic Life Science . ⬇

Calling all member companies – secure your spot at 𝗦𝘄𝗲𝗱𝗲𝗻𝗕𝗜𝗢 𝗦𝘂𝗺𝗺𝗶𝘁! ✨ This week is your last chance to secure a seat at our annual winter gathering. Until Monday we prioritise one attendee per company but starting next week, we release the remaining seats on a first come-first-served basis. 𝗩𝗲𝗻𝘂𝗲: Grand Hôtel, Stockholm 𝗧𝗶𝗺𝗲 & 𝗱𝗮𝘁𝗲: December 11th 13.00 Curious about the program or want to register? Take a look here: https://lnkd.in/dzshJRwn

👋 Join us in welcoming the new members to the SwedenBIO family! 🎉 Mavatar Mavatar is transforming modern medicine and personal healthcare with AI precision medicine using digital twin technology. Based on 20 years R&D, they have developed digital copies of humans and diseases on a molecular level, which they define as digital twins or medical avatars. With their revolutionary AI algorithms and Big Data framework, they enable unimaginable possibilities in healthcare. Christina Forselius AB Christina Forselius AB provides consultancy, interim management, and advisory services within the Life Science area, including project management, leadership, process optmisation and change management. SRS - Scandinavian Regulatory Services AB Scandinavian Regulatory Services (SRS) provides expert regulatory and quality support to bring new and established medical devices, generic and established pharmaceuticals, and combination products to the market. APNC Sweden APNC Sweden is a statistical consulting company that specializes in offering statistical services within life science research. With nearly two decades of experience in the field, they have unique expertise in statistics and clinical research. Their focus is on registry-based studies of real-world data, epidemiological studies and randomized controlled trials. 𝗝𝗼𝗶𝗻 𝘂𝘀! 🤝 As a member of SwedenBIO, your company and all employees get direct access to an extensive network, knowledge of the industry, a strong voice in the debate and useful offers and discounts. Together we advance the development of the Swedish #lifescience industry. Contact our Community Manager, Linn Mattsson , about joining.

National pavilions at major industry events play a crucial role for countries aiming to attract interest from investors and large companies. A pavilion signals a country’s commitment and willingness to welcome actors to its national arena. The Swedish pavilion at this year's BIO-Europe, under the leadership of Business Sweden , was a success that needs to be replicated at other international life science-events.

#𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲𝗦𝘄𝗲𝗱𝗲𝗻 The unlikely story of the Swedish nurse who invented one of the most ubiquitous medtech devices. Barbro Hjalmarsson, a Swedish nurse and healthcare teacher born in 1919, grew frustrated with the repetitive task of manually turning blood samples for analysis. Each sample required 10–15 rotations to mix with an anticoagulant properly—a tedious process that, if done improperly, could result in inaccurate analyses and diagnoses. Driven by her frustration and curiosity, she invented the blood cradle, a device now used worldwide to streamline the process and ensure reliable results. What other Swedish life science innovations have had a lasting global impact? #Sweden #lifescience #biotech #medtech

Timely update of the Swedish life science strategy stating: "Det internationella utbytet är nödvändigt för att främja nytänkande, stimulera utbyte av forskningsidéer och öka innovations- och konkurrenskraften. Sveriges styrkeområden behöver därför synliggöras ytterligare internationellt." This is what #BIOEurope , #NLSDays and other life science partnering events are all about.

BIO-Europe brought both excitement and hard work for the SwedenBIO team. We’re proud to help put Sweden and our thriving life science ecosystem on the map. Most of all, we’re grateful to all the participants—members and non-members alike—who joined forces to make Sweden shine over three vibrant days. Tack! Read our summary of BIO-Europe in Stockholm 👇

SwedenBIO kommenterar den nya life science-strategin i branschmedia. SwedenBIOs Science Director Maja Neiman kommenterar den uppdaterade strategin i Läkemedelsmarknaden.

Metric
Company Name	SwedenBIO	AstraZeneca PLC	Bayer Aktiengesellschaft	CELLINK
Symbol		AZN	BAYN
MSH ID	SE:SWEDENBIO	COM:ASTRAZENECA	COM:BAYER	COM:CELLINK
Market	PRIVATE	STOCKS	STOCKS	PRIVATE
Sector	Healthcare & Health Services	Healthcare	Healthcare	Healthcare & Health Services
Industry	Life Science	Drug Manufacturers - General	Drug Manufacturers - General	Biotechnology Research
Country	SE	GB	DE
Stage
Employee Count		89.90K	98.19K	251
Website	swedenbio.se	astrazeneca.com	bayer.com	cellink.com
LinkedIn	swedenbio	astrazeneca	bayer
Founders

Metric
Market Cap		2.39B	27.44B
Enterprise Value
Monthly Web Traffic	318	758.60K		24.94K
Web Traffic Growth	2.70	-0.13		-0.38
Valuation
Raised Capital				211.14K

Metric
Revenue	45.81B	50.32B
Revenue (LTM)
Revenue (NTM)
Gross Profit	37.54B	29.46B
EBITDA	13.91B	13.04B
Operating Income	8.19B	8.88B
Net Income	5.96B	-3.11B
EPS	3.84	-3.16
Diluted EPS	3.81	-3.16
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.82	0.59
Operating Profit Margin	0.19	0.08
EBITDA Margin	0.30	0.26
Net Profit Margin	0.13	-0.03
Return on Equity	0.17	-0.04
Return on Assets	0.06	-0.01
Return on Capital Employed	0.12	0.04

SWED

SE:SWEDENBIO

SwedenBIO

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	34.12	-7.66
P/B Ratio	5.41	0.84
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.51	0.63
EV Multiple	16.93	-0.89

Metric
Days Sales Outstanding
Days Payables Outstanding	846.26	118.44
Days Inventory Outstanding	239.45	257.77
Operating Cycle	317.44	389.93
Cash Conversion Cycle	95.22	270.05
Asset Turnover	0.47	0.39

Metric
Operating Cash Flow	10.35B	4.29B
Free Cash Flow	6.57B	1.38B
Cash Flow to Debt	0.36	0.16
Operating Cash Flow/Sales	0.23	0.16
Free Cash Flow Yield	0.03	-0.02

Metric
Cash & Equivalents	5.84B	6.24B
Accounts Receivable		727.74M
Inventory	5.42B	14.73B
Goodwill	20.05B	34.12B
Debt to Capitalization	0.48	0.57
Debt to Assets	0.30	0.41
Current Ratio	0.79	1.13
Quick Ratio	0.70	0.87

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.23	0.12
SG&A to Revenue		0.05